FDA cleared Rocket Pharma’s gene therapy for severe leukocyte adhesion deficiency type 1 (LAD-1), marketed as Kresladi, after a prior 2024 rejection linked to manufacturing concerns. The one-time treatment is approved for children without a matched sibling for stem cell transplant, maintaining the standard-of-care role of transplantation while adding a targeted alternative for an ultra-rare population.